NKIO Seed
London, GB · 3 known investors
NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.
BiotechDeep TechHealthtech
Founders & leadership
HB
Hugh BradyCo-founder
MJ
Matthew J. FuchterCo-founder
Investors · 3
Frequently asked questions
- What does NKIO Seed do?
- NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.
- Who founded NKIO Seed?
- NKIO Seed was founded by Hugh Brady, Matthew J. Fuchter.
- Who are NKIO Seed's investors?
- NKIO Seed's investors include Cambridge Angels group, Future Planet Capital, UK Innovation & Science Seed Fund.
- Where is NKIO Seed headquartered?
- NKIO Seed is headquartered in London, GB.